News

2 Closed-End Funds Worth A ‘Buy’

1 Mins read

This article was written by

Nick Ackerman is a former financial advisor using his experience to provide coverage on closed-end funds and exchange-traded funds. Nick has previously held Series 7 and Series 66 licenses and has been investing personally for over 14 years.He contributes to the investing group CEF/ETF Income Laboratory along with leader Stanford Chemist, and Juan de la Hoz and Dividend Seeker. They help members benefit from income and arbitrage strategies in CEFs and ETFs by providing expert-level research. The service includes: managed portfolios targeting safe 8%+ yields, actionable income and arbitrage recommendations, in-depth analysis of CEFs and ETFs, and a friendly community of over a thousand members looking for the best income ideas. These are geared towards both active and passive investors. The vast majority of their holdings are also monthly-payers, which is great for faster compounding as well as smoothing income streams. Learn More.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of BDJ either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Read the full article here

Related posts
News

Cardiff Oncology Stock: Market Dismisses Onvansertib's Potential In Colorectal Cancer

1 Mins read
This article was written by Follow Biologics is a full-time healthcare investor who developed a passion for biotech and life saving therapies…
News

Generation Investment Management Senior Partner Letter

9 Mins read
Dear fellow investors The year 2025 was marked by escalating ‘climate realism’ – a new and cynical term for climate denialism –…
News

Top 25 High-Yield Dividend Stocks For April 2026

1 Mins read
This article was written by Follow I have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting….
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *